Results 1 to 10 of about 9,215 (199)

UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD‐L1 Transcription [PDF]

Advanced Science
Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying mechanisms remain inadequately understood. In this study, we found that the E2/E3 hybrid ubiquitin enzyme UBE2O interacted
Huichan Xue, Xiaohua Jie, Zhiwei Liu, Ruoxin Fang, Shuo Wu, Xiaorong Dong, Shuangbing Xu   +6 more
doaj   +3 more sources

Radioimmunotherapy for Solid Tumors: Spotlight on Glypican-1 as a Radioimmunotherapy Target

Therapeutic Advances in Medical Oncology, 2021
Radioimmunotherapy (i.e., the use of radiolabeled tumor targeting antibodies) is an emerging approach for the diagnosis, therapy, and monitoring of solid tumors.
Maria Lund, Douglas H Campbell, Howard Gurney   +2 more
exaly   +2 more sources

Tellurium-Driven Maple Leaf-Shaped Manganese Nanotherapeutics Reshape Tumor Microenvironment via Chemical Transition in Situ to Achieve Highly Efficient Radioimmunotherapy of Triple Negative Breast Cancer

Bioactive Materials, 2023
The therapeutic efficacy of radioimmunotherapy against triple negative breast cancer (TNBC) is largely limited by the complicated tumor microenvironment (TME) and its immunosuppressive state.
Tianfeng Chen, Zhenyu Ju, Qinghua Liu
exaly   +3 more sources

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis [PDF]

Advanced Science
Purpose: The combination of radiotherapy and immunotherapy (radioimmunotherapy) shows promising antitumor efficacy but raises cardiotoxicity concerns. The underlying mechanisms remain unclear.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
doaj   +2 more sources

Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio‐Immunotherapy [PDF]

Advanced Science
The immunosuppressive tumor microenvironment (TME) promotes resistance to radiation therapy, substantially limiting the efficacy of radioimmunotherapy. Here, we report a hyaluronic acid (HA)‐coated manganese–platinum (MnPt) bimetallic nanozyme (HD@MnO2 ...
Wenyi Zhang, Yangyang Guo, Guoping Xu, Luhaoxiang Liu, Lin Chen, Cai Zhang, Yiming Li, Jianmin Li, Yang Zhao   +8 more
doaj   +2 more sources

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

Journal for ImmunoTherapy of Cancer, 2020
Background Radioimmunotherapy has a promising antitumor effect in hepatocellular carcinoma (HCC), depending on the regulatory effect of radiotherapy on tumor immune microenvironment.
Hui Wang, Yan Huang, Jian Wang, Hailong Sheng, Yazhi Xiao, Zhenru Zhu, Mengying Shen, Peitao Zhou, Zeqin Guo, Wencong Dai, Wanjun Zhang, Jingyuan Sun, Chuanhui Cao   +12 more
doaj   +1 more source

Combination of bacterial-targeted delivery of gold-based AIEgen radiosensitizer for fluorescence-image-guided enhanced radio-immunotherapy against advanced cancer

Bioactive Materials, 2023
Aggregation-Induced Emission luminogen (AIEgen) possess great potential in enhancing bioimaging-guided radiotherapeutic effects and radioimmunotherapy to improve the therapeutic effects of the tumor with good biosafety. Bacteria as a natural carrier have
Yanhong Duo, Zide Chen, Zihuang Li, Xing Li, Yaoqiang Yao, Tianzhao Xu, Ge Gao, Guanghong Luo   +7 more
doaj   +1 more source

Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer

Cell Death Discovery, 2022
Radiation resistance and unsatisfactory efficacy of radioimmunotherapy are important barriers to non-small cell lung cancer (NSCLC) treatment. The impacts of anlotinib on radiation and tumor immune microenvironment (TIME) in NSCLC remain to be resolved ...
Dong Han, Jiajia Zhang, Yawei Bao, Lei Liu, Ping Wang, Dong Qian   +5 more
doaj   +1 more source

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer

Frontiers in Oncology, 2013
Radioimmunotherapy has demonstrated efficacy with acceptable toxicity leading to approval in non-Hodgkin’s lymphoma, but has been slower to develop for the treatment of advanced solid tumors.
Scott T Tagawa, Scott T Tagawa, Naveed Hassan Akhtar, Anastasia eNikolopoulou, Gurveen eKaur, Brian eRobinson, Renee eKahn, Shankar eVallabhajosula, Stanley J Goldsmith, David M Nanus, David M Nanus, Neil H Bander   +11 more
doaj   +1 more source

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor

Frontiers in Oncology, 2021
Desmoplastic small round cell tumor (DRSCT) is a highly aggressive primitive sarcoma that primarily affects adolescent and young adult males. The 5-year survival rate is 15-30% and few curative treatment options exist.
Madelyn Espinosa-Cotton, Nai-Kong V. Cheung   +1 more
doaj   +1 more source